Annexon (ANNX) vs Geron (GERN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Annexon (ANNX) has outperformed Geron (GERN) over the past year, gaining 27.0% versus a loss of 11.6%. Over five years, GERN leads with a -13.5% price change compared with -81.8% for ANNX. Geron is the larger company by market cap ($783.8 million vs $758.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANNX | GERN |
|---|---|---|
| Share price | $4.00 | $1.22 |
| Market cap | $758.32M | $783.82M |
| 1-day change | -0.25% | +1.67% |
| YTD return | -20.32% | -7.58% |
| 1-year return | +26.98% | -11.59% |
| 5-year return | -81.82% | -13.48% |
| Forward P/E | — | 30.50 |
| EPS (TTM) | $-1.13 | $-0.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.18 | $2.01 |
| 52-week low | $2.54 | $1.04 |
| Distance from 52-week high | -44.29% | -39.30% |
| Analyst consensus | buy | none |
| Avg. price target upside | +285.75% | +248.36% |
| Average volume | 3.11M | 10.07M |
| Shares outstanding | 189.58M | 642.47M |
| Employees | 92 | 258 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANNX has outperformed GERN by 38.6 percentage points over the past year.
- The two companies sit in different sectors: Annexon in Healthcare and Geron in Health Care.
About Annexon
ANNX stock →Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis.
Healthcare · Biotechnology · 92 employees
About Geron
GERN stock →Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML.
Health Care · Biotechnology: Pharmaceutical Preparations · 258 employees
ANNX vs GERN FAQ
Which is bigger, Annexon or Geron?
Geron (GERN) is larger, with a market capitalization of $783.82M compared with $758.32M for Annexon (ANNX).
Which stock has performed better over the past year, ANNX or GERN?
ANNX returned +26.98% over the past 12 months, compared with -11.59% for GERN (price return, excluding dividends). Past performance does not predict future results.
Are Annexon and Geron in the same industry?
No. Annexon is in the Healthcare sector, while Geron is in Health Care.